S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda

Cardinal Health (CAH) Competitors

$108.19
+2.19 (+2.07%)
(As of 04/19/2024 ET)

CAH vs. COR, MCK, ZBH, RMD, WST, ICLR, BIIB, ALGN, ARGX, and MOH

Should you be buying Cardinal Health stock or one of its competitors? The main competitors of Cardinal Health include Cencora (COR), McKesson (MCK), Zimmer Biomet (ZBH), ResMed (RMD), West Pharmaceutical Services (WST), ICON Public (ICLR), Biogen (BIIB), Align Technology (ALGN), argenx (ARGX), and Molina Healthcare (MOH). These companies are all part of the "medical" sector.

Cardinal Health vs.

Cencora (NYSE:COR) and Cardinal Health (NYSE:CAH) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, analyst recommendations, risk and dividends.

97.5% of Cencora shares are owned by institutional investors. Comparatively, 87.2% of Cardinal Health shares are owned by institutional investors. 15.8% of Cencora shares are owned by insiders. Comparatively, 0.2% of Cardinal Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cencora presently has a consensus target price of $218.22, indicating a potential downside of 8.74%. Cardinal Health has a consensus target price of $103.07, indicating a potential downside of 4.73%. Given Cencora's higher possible upside, analysts clearly believe Cardinal Health is more favorable than Cencora.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cencora
0 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.63
Cardinal Health
1 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.55

Cencora has a net margin of 0.69% compared to Cencora's net margin of 0.30%. Cardinal Health's return on equity of 323.23% beat Cencora's return on equity.

Company Net Margins Return on Equity Return on Assets
Cencora0.69% 323.23% 4.13%
Cardinal Health 0.30%-57.44%3.89%

Cardinal Health received 163 more outperform votes than Cencora when rated by MarketBeat users. Likewise, 71.66% of users gave Cardinal Health an outperform vote while only 65.03% of users gave Cencora an outperform vote.

CompanyUnderperformOutperform
CencoraOutperform Votes
727
65.03%
Underperform Votes
391
34.97%
Cardinal HealthOutperform Votes
890
71.66%
Underperform Votes
352
28.34%

Cencora has higher revenue and earnings than Cardinal Health. Cencora is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cencora$262.17B0.18$1.75B$9.1826.05
Cardinal Health$205.01B0.13$261M$2.5442.59

Cencora pays an annual dividend of $2.04 per share and has a dividend yield of 0.9%. Cardinal Health pays an annual dividend of $2.00 per share and has a dividend yield of 1.8%. Cencora pays out 22.2% of its earnings in the form of a dividend. Cardinal Health pays out 78.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Cencora has raised its dividend for 1 consecutive years and Cardinal Health has raised its dividend for 27 consecutive years. Cardinal Health is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Cencora and Cencora both had 14 articles in the media. Cencora's average media sentiment score of 1.10 beat Cardinal Health's score of 0.14 indicating that Cardinal Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cencora
2 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Cardinal Health
8 Very Positive mention(s)
3 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cencora has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Cardinal Health has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

Summary

Cencora beats Cardinal Health on 11 of the 20 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CAH vs. The Competition

MetricCardinal HealthDrugs, proprietaries, & sundries IndustryMedical SectorNYSE Exchange
Market Cap$26.32B$15.18B$4.89B$17.26B
Dividend Yield1.85%1.23%2.93%3.59%
P/E Ratio42.5933.21152.3920.72
Price / Sales0.132.372,467.199.63
Price / Cash12.469.9647.3117.28
Price / Book-9.6613.184.564.85
Net Income$261M$665.71M$104.37M$970.56M
7 Day Performance2.94%0.76%-4.52%-1.76%
1 Month Performance-3.86%-10.18%-6.80%-4.32%
1 Year Performance35.10%9.79%6.60%92.59%

Cardinal Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
COR
Cencora
3.8037 of 5 stars
$238.30
+1.7%
$218.22
-8.4%
+44.1%$47.54B$262.17B25.9646,000Insider Selling
News Coverage
MCK
McKesson
4.7082 of 5 stars
$528.42
+1.1%
$533.50
+1.0%
+46.1%$69.44B$276.71B23.9451,000
ZBH
Zimmer Biomet
4.7799 of 5 stars
$122.07
-1.6%
$139.39
+14.2%
-13.7%$25.08B$7.39B24.9618,000News Coverage
Positive News
RMD
ResMed
4.8237 of 5 stars
$184.85
-0.1%
$199.20
+7.8%
-20.5%$27.19B$4.22B30.5510,140Upcoming Earnings
News Coverage
WST
West Pharmaceutical Services
4.7857 of 5 stars
$379.48
+0.2%
$435.20
+14.7%
+2.9%$27.78B$2.95B48.1610,600Upcoming Earnings
Analyst Revision
News Coverage
ICLR
ICON Public
4.5905 of 5 stars
$294.03
-1.7%
$319.45
+8.6%
+39.8%$24.26B$8.12B39.8441,100Upcoming Earnings
Short Interest ↓
News Coverage
BIIB
Biogen
4.9189 of 5 stars
$195.15
-0.8%
$298.96
+53.2%
-33.0%$28.37B$9.84B24.457,570Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
ALGN
Align Technology
4.8462 of 5 stars
$305.10
+0.1%
$339.91
+11.4%
-15.2%$22.96B$3.86B52.4221,610Upcoming Earnings
Analyst Report
News Coverage
ARGX
argenx
3.7839 of 5 stars
$370.68
-1.5%
$530.74
+43.2%
-5.2%$21.98B$1.27B-72.121,148Analyst Report
Analyst Revision
News Coverage
MOH
Molina Healthcare
4.7427 of 5 stars
$357.41
-1.0%
$393.09
+10.0%
+33.1%$20.94B$34.07B19.03123,123Upcoming Earnings

Related Companies and Tools

This page (NYSE:CAH) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners